Navigation Links
Combining diagnostic tests more accurate at predicting Alzheimer's
Date:12/10/2012

DURHAM, N.C. -- Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

The findings, which appear Tuesday, Dec. 11, 2012, in the journal Radiology, provide new insight into how to accurately detect Alzheimer's before the full onset of the disease.

Duke researchers studied three tests magnetic resonance imaging (MRI), fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET), and cerebrospinal fluid analysis to determine whether the combination provided more accuracy than each test individually. The tests were added to routine clinical exams, including neuropsychological testing, currently used to diagnose Alzheimer's disease.

"This study marks the first time these diagnostic tests have been used together to help predict the progression of Alzheimer's. If you use all three biomarkers, you get a benefit above that of the pencil-and-paper neuropsychological tests used by doctors today," said Jeffrey Petrella, MD, associate professor of radiology at Duke Medicine and study author. "Each of these tests adds new information by looking at Alzheimer's from a different angle."

Alzheimer's disease affects more than 30 million people worldwide, and the number is expected to triple by 2050. Research suggests that Alzheimer's begins years to decades before it is diagnosed, with patients experiencing a phase with some memory loss, or mild cognitive impairment, before the disease's full onset. Patients with mild cognitive impairment are at a higher risk for having Alzheimer's, but not everyone will progress to developing the disease.

While there is no cure for Alzheimer's, new treatments under study are likely to be most effective at the disease's earliest stages. Researchers are working to improve early detection of Alzheimer's, even before patients experience symptoms, but the disease remains difficult to diagnose and patients are often misclassified.

"Misdiagnosis in very early stages of Alzheimer's is a significant problem, as there are more than 100 conditions that can mimic the disease. In people with mild memory complaints, our accuracy is barely better than chance. Given that the definitive gold standard for diagnosing Alzheimer's is autopsy, we need a better way to look into the brain," said P. Murali Doraiswamy, MBBS, professor of psychiatry and medicine at Duke and study author.

"Physicians vary widely in what tests they perform for diagnosis and prognosis of mild memory problems, which in turn affects decisions about work, family, treatment and future planning."

The Duke team analyzed data from 97 older adults with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative, a national study that collects data in hundreds of elderly patients with varying levels of cognitive impairment. Participants took part in clinical cognitive testing, as well as the three diagnostic exams: MRI, FDG-PET, and cerebrospinal fluid analysis. They then checked in with doctors for up to four years.

The misclassification rate based solely on neuropsychological testing and other clinical data was relatively high at 41.3 percent. Adding each of the diagnostic tests reduced the number of misdiagnoses so that, with all three tests combined, researchers achieved the lowest misclassification rate of 28.4%.

Of the three individual diagnostic tests, FDG-PET added the most information to clinical testing to detect early Alzheimer's in patients with mild cognitive impairment.

Researchers noted that while the tests clearly provided the most diagnostic information in combination, additional studies are needed to better understand their role in a clinical setting.

"The study used a unique data-mining algorithm to analyze MRI and PET images for 'silent' information that may not be apparent to the naked eye. Hence, the data should not be taken to mean that imaging should be done in every patient; rather, it sought to capture the maximum potential information available in the images," Petrella said.

"Additional studies, including those looking at the cost effectiveness of these tests, are also needed to translate the most useful biomarkers into clinical practice."

Earlier this year, a multicenter study led by Doraiswamy found that another type of PET scan that tags amyloid plaques in the brains of people with Alzheimer's also helped predict the onset of the disease in those with mild cognitive impairment. Adding amyloid plaque imaging in future studies could supplement the tests used in this research, providing even more diagnostic information.

In addition to Petrella and Doraiswamy, study authors include Jennifer L. Shaffer, MD; Forest C. Sheldon, BS; Kingshuk Roy Choudhury, PhD; and R. Edward Coleman, MD (who died in June 2012) of the Department of Radiology at Duke University Medical Center. Vince D. Calhoun, PhD, of the Mind Research Network and the Department of Electrical and Computer Engineering at the University of New Mexico, also authored this research.


'/>"/>

Contact: Rachel Bloch Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
2. Is Combining Hysterectomy and a Tummy Tuck Safe?
3. Psychiatry Gets Revised Diagnostic Manual
4. Society of Diagnostic Medical Sonography Foundation introduces Sonography Research Institute
5. Novel breast screening technology increases diagnostic accuracy
6. UMSOM dean urges caution in revising diagnostic guidelines for gestational diabetes
7. BIDMC and Diagnostics For All create first low-cost, paper-based, point of care liver function test
8. Non-invasive diagnostic imaging costs to Medicare Part B down significantly since 2006
9. Diagnostic test shows potential to noninvasively identify significant coronary artery disease
10. Racial differences in diabetes diagnostic thresholds
11. Diagnostic imaging increases among stage IV cancer patients on Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: